August 27, 2013 at 11:40 AM EDT
Five Star Equities Issues New Research Reports on AMGN, IMMU, MRGE and RIGL

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

Amgen, Inc. (NASDAQ: AMGN) shares spiked 7.72 percent to close at $113.75 a share Monday. The stock traded between $110.75 and $116.25 on volume of 11.54 million shares traded. The company announced it has agreed to acquire Onyx Pharmaceuticals, Inc. for approximately $10.4 billion. Shares of Amgen have fallen approximately 32.0 percent year-to-date.

Get more information on Amgen and free access to the in-depth equity report at:

www.FiveStarEquities.com/AMGN

Immunomedics, Inc. (NASDAQ: IMMU) shares jumped 7.71 percent to close at $6.15 a share Monday. The stock traded between $5.74 and $6.54 on volume of 4.04 million shares traded. The company reported revenues were $1.4 million for the fourth quarter of fiscal 2013, an increase of $0.4 million when compared to a year ago. Shares of Immunomedics have gained approximately 110.0 percent year-to-date.

Get more information on Immunomedics and free access to the in-depth equity report at:

www.FiveStarEquities.com/IMMU

Merge Healthcare Inc. (NASDAQ: MRGE) shares surged 8.30 percent to close at $2.61 a share Monday. The stock traded between $2.48 and $2.65 on volume of 1.98 million shares traded. The company announced that Michael W. Ferro, Jr. has stepped down as Chairman. Shares of Merge Healthcare have gained approximately 5.0 percent year-to-date.

Get more information on Merge Healthcare and free access to the in-depth equity report at:

www.FiveStarEquities.com/MRGE

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares dropped 13.50 percent to close at $3.14 a share Monday. The stock traded between $3.00 and $3.39 on volume of 3.22 million shares traded. The company announced that R343 did not meet its primary or secondary endpoints in a recent asthma study. Shares of Rigel Pharmaceuticals have fallen approximately 52.0 percent year-to-date.

Get more information on Rigel Pharmaceuticals and free access to the in-depth equity report at:

www.FiveStarEquities.com/RIGL

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:

Five Star Equities

info@fivestarequities.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here